MYOSARCII: Accuracy of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy
Study Details
Study Description
Brief Summary
The development of precise and non-invasive diagnostic methods is a priority in areas such as gynaecology and oncology, and above all in improving the health of those patients with a surgical indication for hysterectomy, laparoscopic or laparotomic myomectomy for diagnosis of uterine tumours. Indeed, in the absence of an accurate and objective preoperative diagnostic option, all patients with suspected benign tumours should be considered at risk for occult leiomyosarcoma.
Recently, the concept of "liquid biopsy" has emerged as a minimally invasive alternative to surgical biopsies for solid tumours with highly recurrent mutations, avoiding the sampling of tumour tissue before and after treatment. Generally, the liquid biopsy is obtained by taking a sample of blood or other body fluids, to provide tumour-specific information.
Based on these premises, a prospective, observational and multicentre case-control study is proposed, the objective of which is to evaluate the diagnostic precision (sensitivity, specificity, negative predictive value and positive predictive value) in the detection of molecular differences by liquid biopsy in patients with suspected myometrial tumour (leiomyoma / leiomyosarcoma).
Depending on the results of these analysis, the application of this technology could allow the differential diagnosis of the tumour in a non-invasive and objective way, as well as the development of biomarkers and effective targeted therapies in the treatment of leiomyosarcomas. Consequently, we would also be increasing our knowledge of tumour biology and associated pathologies in a clinical and therapeutic context.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Recently, the concept of "liquid biopsy" has emerged as a minimally invasive alternative to surgical biopsies. Generally, the liquid biopsy is obtained by taking a sample of blood or other body fluids, to provide tumour-specific information.
The use of technologies such as high-throughput sequencing or Next Generation Sequencing (NGS) could be an effective method for the detection of molecular differences from circulating genetic material in peripheral blood of patients with suspected myometrial tumour (leiomyoma / leiomyosarcoma), versus patients without tumour pathologies.
This is a prospective, multicentre, national biomedical case-control study aimed at patients with a surgical indication for hysterectomy or myomectomy due to the diagnosis of myometrial tumours (leiomyoma / leiomyosarcoma) according to standard clinical practice.
Once the study is approved by the Research Ethics Committee (CEI) of the Hospital, we will proceed to the recruitment and selection of those patients who meet the inclusion criteria.
After obtaining informed consent, peripheral blood will be collected from the candidate patient, prior to the surgery that the patient had already planned for medical indication in accordance with the usual clinical practice or, in the case of control patients, during an analysis or gynaecological consultation that was already planned to be performed by routine clinical practice. These samples will be sent to the Igenomix Foundation laboratories for molecular study.
Finally, and once both molecular and histological results are obtained, the precision of the determination of the molecular results will be compared with the "gold standard" in the diagnosis of myometrial tumours through two expert evaluators in pathological anatomy.
In this way, if the hypothesis raised is confirmed and the proposed objectives are achieved, we would be demonstrating the viability of a minimally invasive and precise preoperative diagnostic approach, based on the molecular characterization of leiomyoma and leiomyosarcoma.
When calculating the sample size for our study, we have considered the main objective, which is the validation of the test, comparing it with the "gold standard" of pathological anatomy. To calculate the sensitivity and specificity of the test, we would need a minimum of 200 LMS samples, 200 LM samples, and 200 control patient samples for validation.
It is intended to establish a cut-off point with a preliminary analysis in the first 30 patients (10 first patients from each group), in which the laboratory data are combined with those derived from the Pathological Anatomy (Gold Standard).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Leiomyoma samples Leiomyoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour |
Procedure: Collection of Leiomyoma samples
Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.
A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis.
Other Names:
|
| Leiomyosarcoma samples Leiomyosarcoma samples and peripheral blood samples obtained from women between 18 and 80 years with suspected myometrial tumour |
Procedure: Collection of Leiomyosarcoma samples
Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.
A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis.
Other Names:
|
| Control samples Peripheral blood samples obtained from women between 18 and 80 years without suspected myometrial tumour |
Procedure: Collection of control samples
Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Diagnostic precision of uterine tumours at molecular level [25 months]
Sensitivity, specificity, negative predictive value and positive predictive value of the molecular diagnosis of uterine tumours by liquid biopsy as a preoperative diagnosis, using pathological diagnosis as a "gold standard" to validate the molecular diagnosis.
Secondary Outcome Measures
- Concordance of Circulating tumour DNA / RNA versus DNA / RNA in tumour [25 months]
Determine the concordance of circulating tumour DNA / RNA in plasma (ctRNA / ctDNA) versus the contribution of tumour tissue DNA / RNA in determining the diagnosis and histological subtype
- Inter-observer variability [25 months]
Inter-observer variability in determining the histological diagnosis of uterine tumours in the analysis performed by pathologists
- Evaluation of Circulating tumour DNA / RNA profile for oncological outcome [25 months]
Contribution of the plasma circulating tumour DNA / RNA profile (ctRNA / ctDNA) in determining the oncological outcome (survival, disease-free interval)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients who voluntarily sign the informed consent approved by the Research Ethics Committee (CEI) after having been duly informed of the nature of the study, before carrying out any test related to it, knowing the potential risks, benefits and discomforts derived from their participation. Participants should be informed that they may leave the study at any time, without this entailing any consequence for their subsequent medical care.
-
BMI = 18.5-40 kg / m2
-
Age = 18-80 years
-
Surgical indication according to usual clinical practice, due to suspicion of a tumour mass in the uterus, either primary (stages I-IV) or recurrence, but without prior chemotherapy or radiotherapy (at the time of primary diagnosis or prior to recurrence) .
-
Note: Control patients will have the same inclusion criteria for BMI and age but without uterine tumour pathology.
Exclusion Criteria:
-
Patients who have participated in a clinical trial during the last 30 days unless it is approved by the sponsor as it does not interfere with the current study.
-
Patients who have received chemotherapy or radiotherapy before taking the sample (in case of recurrence).
-
Pregnant patients before or during the duration of the study.
-
Existence of serious or uncontrolled bacterial, fungal, or viral infections (type HPV, HIV, hepatitis) that, in the opinion of the principal investigator, could interfere with the participation of the patient in the study or in the evaluation of the study results.
-
Any disease or medical condition that is unstable or may jeopardize patient safety and compliance in the study. For example: patients with an active history of other malignant tumours.
-
Psychological, family, sociological or geographical situations that do not allow compliance with the protocol or the signing of informed consent.
-
Patients vaccinated with mRNA vaccines in the week before surgery.
-
Note: Control patients will have the same exclusion criteria as patients with tumour pathology
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Universitari de Bellvitge | L´Hospitalet de Llobregat | Barcelona | Spain | |
| 2 | Hospital Universitario de Son LLàtzer de Mallorca | Palma De Mallorca | Islas Baleares | Spain | |
| 3 | Complejo Hospitalario Universitario Insular de Las Palmas | Las Palmas De Gran Canaria | Las Palmas | Spain | |
| 4 | Hospital Universitario de Getafe | Getafe | Madrid | Spain | |
| 5 | Hospital Universitario Puerta de Hierro Majadahonda | Majadahonda | Madrid | Spain | |
| 6 | Complejo Hospitalario de Cartagena | Cartagena | Murcia | Spain | |
| 7 | Complejo Hospitalario de Navarra | Pamplona | Navarra | Spain | |
| 8 | Hospital General de Alicante | Alicante | Spain | ||
| 9 | Hospital Clinic de Barcelona | Barcelona | Spain | ||
| 10 | Hospital del Mar Parc Salut | Barcelona | Spain | ||
| 11 | Hospital Universitario de León | León | Spain | ||
| 12 | Hospital MD Anderson Cancer Center Madrid | Madrid | Spain | ||
| 13 | Hospital Quirón Madrid | Madrid | Spain | ||
| 14 | Hospital Universitario 12 de Octubre de Madrid | Madrid | Spain | ||
| 15 | Hospital Clínico Universitario Virgen de la Arrixaca de Murcia | Murcia | Spain | ||
| 16 | Hospital Regional Universitario de Málaga | Málaga | Spain | ||
| 17 | Hospital Virgen de la Macarena | Sevilla | Spain | ||
| 18 | Hospital Virgen de la Salud de Toledo | Toledo | Spain | ||
| 19 | Hospital Clínico Universitario de Valencia | Valencia | Spain | ||
| 20 | Hospital General Universitario de Valencia | Valencia | Spain | ||
| 21 | Hospital Universitario y Politécnico La Fe de Valencia | Valencia | Spain |
Sponsors and Collaborators
- Igenomix
Investigators
- Study Chair: Carlos Simón, MD, PhD, Igenomix
- Principal Investigator: Aymara Mas, PhD, Igenomix Foundation
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IGX1-DTU-AM-21-03